查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1427050

全球原代肝細胞市場-全球產業分析、規模、份額、成長、趨勢、預測(2031)-按產品、類型、按應用或分析、按最終用戶、按地區

Primary Hepatocytes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 316 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

未來 10 年，全球原代肝細胞市場規模預計將以 8.0% 的年增長率 (CAGR) 成長，到 2031 年將達到 4.1 億美元。成長預期。 這一充滿希望的軌跡反映了對肝細胞的需求不斷增加，因為它們在藥物開發、測試和新癌症治療方法的開發中發揮著重要作用。

在潛在候選藥物分析中常規使用肝細胞可以加速新藥的開發並加速其進入臨床試驗。 測試模型的可靠性極大地影響新藥研發的成敗，而肝細胞在過程中的作用極為重要。

隨著科技的進步，對動物模型的依賴逐漸減少，取而代之的是越來越類似體內的系統。 預計這一趨勢將在可預見的未來推動對原代肝細胞的需求。

癌症盛行率的上升和對癌症治療的需求不斷增加正在刺激涉及原代肝細胞的研究。 個人化醫療根據患者個別特徵提供量身定制的治療方案，依靠原代肝細胞來開發個人化藥物。 因此，隨著對個人化治療的需求不斷增長，原代肝細胞市場也在不斷增長。

本報告調查了全球原代肝細胞市場，並提供了市場概述，包括按產品、類型、應用或分析、最終用戶、區域以及進入市場的公司的競爭趨勢劃分的趨勢。

目錄

第 1 章執行摘要

第 2 章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • PESTLE分析

第 3 章2018-2023年生產與貿易統計

第 4 章價格分析，2018-2023

第 5 章2018-2031年全球原代肝細胞市場展望

  • 2018-2031 年全球原代肝細胞市場前景（依產品、價值（百萬美元）、數量（百萬單位））
  • 2018-2031 年全球原代肝細胞市場前景、種類、價值（百萬美元）、數量（百萬單位）
  • 2018-2031 年全球原代肝細胞市場展望（按應用或分析）、價值（百萬美元）、數量（百萬單位）
  • 2018-2031 年全球原代肝細胞市場前景（按最終用戶劃分）、價值（百萬美元）、數量（百萬單位）
  • 2018-2031 年全球原代肝細胞市場前景（按地區、價值（百萬美元）、數量（百萬單位））

第 6 章北美原代肝細胞市場展望，2018-2031

第 7 章歐洲原代肝細胞市場展望，2018-2031

第 8 章亞太地區原代肝細胞市場展望，2018-2031

第 9 章拉丁美洲原代肝細胞市場前景，2018-2031

第 10 章中東與非洲原代肝細胞市場展望，2018-2031

第 11 章競爭態勢

  • 產品與應用或檢測熱圖
  • 2022 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Thermo Fisher Scientific
    • Corning Inc.
    • Lonza
    • Axol Bioscience Ltd.
    • LifeNet Health
    • SEKISUI XenoTech, LLC
    • Cytes Biotechnologies
    • Cell Biologics, Inc.
    • ZenBio, Inc.
    • BioIVT.
    • ScienCell Research Laboratories, Inc.
    • Kerafast

第 12 章附錄

簡介目錄

Unveiling Opportunities, Challenges, and Country-wise Insights

Global Market Overview:

The global primary hepatocytes market is poised for significant growth, projected to reach a value of US$ 410 Mn by 2031, with an estimated Compound Annual Growth Rate (CAGR) of 8.0% over the next decade. This promising trajectory reflects the increasing demand for primary hepatocytes, driven by their crucial role in drug development, testing, and the development of new cancer treatments.

Opportunities for Primary Hepatocyte Manufacturers:

The routine adoption of hepatocytes for analyzing potential medication candidates accelerates the development of novel medicines and expedites their entry into clinical trials. The reliability of testing models significantly influences the success of developing novel medication therapies, emphasizing the pivotal role of hepatocytes in this process.

Advancements in technology are progressively reducing the reliance on animal models, favoring increasingly in vivo-like systems. This trend is expected to drive the demand for primary hepatocytes in the foreseeable future.

The growing prevalence of cancer and the escalating demand for cancer therapy have spurred research involving primary hepatocytes. Personalized medicine, which offers tailored treatment options based on individual patient characteristics, relies on primary hepatocytes for the development of personalized medications. Consequently, the market for primary hepatocytes has witnessed parallel growth alongside the rise in demand for personalized therapeutics.

Liver transplantation remains the optimal treatment for hepatic illness caused by various factors such as viruses, oncogenes, medications, or surgical removal. However, the scarcity of suitable liver donors presents challenges in meeting medical demands. To address this issue, alternative options such as hepatocyte transplantation are being explored, driving immediate demand for primary hepatocytes and fostering market development.

Stringent regulations set by various regulatory bodies emphasize ensuring the well-being of animals used in experiments. These regulations, coupled with researchers' self-imposed limits, have led to an increased demand for in-vivo models, presenting opportunities for primary hepatocyte providers to meet these regulatory standards and cater to the growing market demand.

Challenges Impacting Demand:

Despite the promising growth outlook, challenges persist in maintaining the demand for primary hepatocytes. Availability of other cell types for drug screening, along with the high risk of contamination and the intricate maintenance requirements of hepatocytes, pose constraints on market expansion. Additionally, the limited lifespan of freshly-isolated hepatocytes and the susceptibility to contamination hinder their widespread adoption.

Country-wise Insights:

  • United States: With approximately 84.7% market share in the North American primary hepatocytes culture market, the U.S. presents a lucrative landscape fueled by increasing investments in R&D programs and strategic business expansions.
  • Germany: Holding the largest market share in Europe, Germany benefits from the presence of major industry players, fostering accessibility and steady growth in the primary hepatocytes market.
  • China: Emerging as a prominent market, China exhibits substantial growth potential driven by extensive research activities, collaborative initiatives, and significant R&D investments.
  • India: With a considerable share in the South Asia primary hepatocytes market, India showcases a growing adoption of modern medicines and newer therapies, supported by increasing affordability and acceptance of biological drugs.

Competitive Landscape: Leading providers such as Thermo Fisher Scientific, Corning Inc., Lonza, and others are strategically positioning themselves through alliances, product launches, patents, and acquisitions to capitalize on the burgeoning opportunities in the primary hepatocytes industry.

Key Companies Profiled in the market include:

  • Thermo Fisher Scientific
  • Corning Inc.
  • Lonza
  • Axol Bioscience Ltd.
  • LifeNet Health
  • SEKISUI XenoTech, LLC
  • Cytes Biotechnologies
  • Cell Biologics, Inc.
  • ZenBio, Inc.
  • BioIVT.
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Takara Bio Inc.
  • Kosheeka

Key Segments Covered in Primary Hepatocytes Industry Survey

Primary Hepatocytes Market by Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

Primary Hepatocytes Market by Species:

  • Humans
  • Rats
  • Mice
  • Dogs
  • Monkeys
  • Horses
  • Others

Primary Hepatocytes Market by Application or Assay:

  • Cell Viability Assays
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assays
  • In Vitro Intrinsic Clearance
  • Phospholipoids Assays
  • Others

Primary Hepatocytes Market by End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

Primary Hepatocytes Market by Region:

  • North America Primary Hepatocytes Market
  • Latin America Primary Hepatocytes Market
  • Europe Primary Hepatocytes Market
  • South Asia Primary Hepatocytes Market
  • East Asia Primary Hepatocytes Market
  • Oceania Primary Hepatocytes Market
  • The Middle East & Africa Primary Hepatocytes Market

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Primary Hepatocytes Market Production Output, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe x`
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis, by Product/ Species/ Application or Assay/ End User, US$ Per Unit, 2018 - 2023
  • 4.2. Prominent Factor Affecting Primary Hepatocytes Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Primary Hepatocytes Market Outlook, 2018 - 2031

  • 5.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Humans
      • 5.2.1.2. Rats
      • 5.2.1.3. Mice
      • 5.2.1.4. Dogs
      • 5.2.1.5. Monkeys
      • 5.2.1.6. Horses
      • 5.2.1.7. Others
  • 5.3. Global Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assays
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assays
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipoids Assays
      • 5.3.1.7. Others
  • 5.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical Companies
      • 5.4.1.2. Academic and Research Institutes
      • 5.4.1.3. Contract Research Organizations
  • 5.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America Primary Hepatocytes Market Outlook, 2018 - 2031

  • 6.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Humans
      • 6.2.1.2. Rats
      • 6.2.1.3. Mice
      • 6.2.1.4. Dogs
      • 6.2.1.5. Monkeys
      • 6.2.1.6. Horses
      • 6.2.1.7. Others
  • 6.3. North America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assays
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assays
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipoids Assays
      • 6.3.1.7. Others
  • 6.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical Companies
      • 6.4.1.2. Academic and Research Institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.3. U.S. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.7. Canada Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook, 2018 - 2031

  • 7.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Humans
      • 7.2.1.2. Rats
      • 7.2.1.3. Mice
      • 7.2.1.4. Dogs
      • 7.2.1.5. Monkeys
      • 7.2.1.6. Horses
      • 7.2.1.7. Others
  • 7.3. Europe Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assays
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assays
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipoids Assays
      • 7.3.1.7. Others
  • 7.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical Companies
      • 7.4.1.2. Academic and Research Institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.3. Germany Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.7. U.K. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.11. France Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.13. Italy Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.14. Italy Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.15. Italy Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.16. Italy Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.17. Turkey Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.18. Turkey Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.19. Turkey Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.20. Turkey Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.23. Russia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.27. Rest of Europe Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Primary Hepatocytes Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Humans
      • 8.2.1.2. Rats
      • 8.2.1.3. Mice
      • 8.2.1.4. Dogs
      • 8.2.1.5. Monkeys
      • 8.2.1.6. Horses
      • 8.2.1.7. Others
  • 8.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assays
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assays
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipoids Assays
      • 8.3.1.7. Others
  • 8.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical Companies
      • 8.4.1.2. Academic and Research Institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.3. China Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.7. Japan Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.11. South Korea Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.15. India Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.19. Southeast Asia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Primary Hepatocytes Market Outlook, 2018 - 2031

  • 9.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Cryopreserved Suspension Hepatocytes
      • 9.1.1.2. Fresh Suspension Hepatocytes
      • 9.1.1.3. 3D (Spheroid) Hepatocytes
      • 9.1.1.4. Expanded Hepatocytes (Plateable)
      • 9.1.1.5. Non-characterized Hepatocytes
  • 9.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Humans
      • 9.2.1.2. Rats
      • 9.2.1.3. Mice
      • 9.2.1.4. Dogs
      • 9.2.1.5. Monkeys
      • 9.2.1.6. Horses
      • 9.2.1.7. Others
  • 9.3. Latin America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Cell Viability Assays
      • 9.3.1.2. Cytochrome Enzyme Activity
      • 9.3.1.3. High Content Cytotoxicity
      • 9.3.1.4. Transporter Inhibition Assays
      • 9.3.1.5. In Vitro Intrinsic Clearance
      • 9.3.1.6. Phospholipoids Assays
      • 9.3.1.7. Others
  • 9.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Biopharmaceutical Companies
      • 9.4.1.2. Academic and Research Institutes
      • 9.4.1.3. Contract Research Organizations
    • 9.4.2. BPS Analysis/Market Attractiveness Analysis
  • 9.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.3. Brazil Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.7. Mexico Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.9. Argentina Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.10. Argentina Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.11. Argentina Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.12. Argentina Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.13. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.14. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.15. Rest of Latin America Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.16. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Primary Hepatocytes Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Cryopreserved Suspension Hepatocytes
      • 10.1.1.2. Fresh Suspension Hepatocytes
      • 10.1.1.3. 3D (Spheroid) Hepatocytes
      • 10.1.1.4. Expanded Hepatocytes (Plateable)
      • 10.1.1.5. Non-characterized Hepatocytes
  • 10.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Humans
      • 10.2.1.2. Rats
      • 10.2.1.3. Mice
      • 10.2.1.4. Dogs
      • 10.2.1.5. Monkeys
      • 10.2.1.6. Horses
      • 10.2.1.7. Others
  • 10.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Cell Viability Assays
      • 10.3.1.2. Cytochrome Enzyme Activity
      • 10.3.1.3. High Content Cytotoxicity
      • 10.3.1.4. Transporter Inhibition Assays
      • 10.3.1.5. In Vitro Intrinsic Clearance
      • 10.3.1.6. Phospholipoids Assays
      • 10.3.1.7. Others
  • 10.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. Biopharmaceutical Companies
      • 10.4.1.2. Academic and Research Institutes
      • 10.4.1.3. Contract Research Organizations
    • 10.4.2. BPS Analysis/Market Attractiveness Analysis
  • 10.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.2. GCC Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.3. GCC Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.4. GCC Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.7. South Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.8. South Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.9. Egypt Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.10. Egypt Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.11. Egypt Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.12. Egypt Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.15. Nigeria Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.20. Rest of Middle East & Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. Product vs Application or Assay Heatmap
  • 11.2. Company Market Share Analysis, 2022
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Thermo Fisher Scientific
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. Corning Inc.
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. Lonza
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. Axol Bioscience Ltd.
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. LifeNet Health
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. SEKISUI XenoTech, LLC
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Cytes Biotechnologies
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Cell Biologics, Inc.
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development
    • 11.4.9. ZenBio, Inc.
      • 11.4.9.1. Company Overview
      • 11.4.9.2. Product Portfolio
      • 11.4.9.3. Financial Overview
      • 11.4.9.4. Business Strategies and Development
    • 11.4.10. BioIVT.
      • 11.4.10.1. Company Overview
      • 11.4.10.2. Product Portfolio
      • 11.4.10.3. Financial Overview
      • 11.4.10.4. Business Strategies and Development
    • 11.4.11. ScienCell Research Laboratories, Inc.
      • 11.4.11.1. Company Overview
      • 11.4.11.2. Product Portfolio
      • 11.4.11.3. Financial Overview
      • 11.4.11.4. Business Strategies and Development
    • 11.4.12. Kerafast
      • 11.4.12.1. Company Overview
      • 11.4.12.2. Product Portfolio
      • 11.4.12.3. Financial Overview
      • 11.4.12.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations